ASCO: Sotorasib Targets KRAS p.G12C-Mutated NSCLC
WEDNESDAY, June 9, 2021 -- Sotorasib therapy yields clinical benefit for patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer (NSCLC), according to a study published online June 4 in the New England Journal of Medicine to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Study